SCHEMBL754265

SCHEMBL754265

CN(C)C(C)(C(=O)O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.50
CHRM3 P20309 1/20 0.49
KCNN4 O15554 2/20 0.48
MAPT P10636 1/20 0.47
KMT2A Q03164 1/20 0.47
CYP2C19 P33261 1/20 0.45
HIF1A Q16665 1/20 0.45
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
HDAC9 Q9UKV0 1/20 0.44
HDAC5 Q9UQL6 1/20 0.44
CYP2D6 P10635 1/20 0.42
OPRM1 P35372 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2089572 1.00 CYP1A2 (0.50) CYP1A2CHRM3KCNN4MAPTKMT2A
SCHEMBL2089573 1.00 CYP1A2 (0.50) CYP1A2CHRM3KCNN4MAPTKMT2A
SCHEMBL13389065 0.85 CHRM3 (0.48) CYP1A2CHRM3KCNN4MAPTKMT2A
SCHEMBL18901727 0.83 CHRM3 (0.47) CYP1A2CHRM3KCNN4MAPTKMT2A
SCHEMBL6904216 0.83 MAPT (0.59) CYP1A2CHRM3KCNN4MAPTKMT2A
SCHEMBL17827512 0.82 CES1 (0.50) CYP1A2CHRM3KCNN4MAPTKMT2A
SCHEMBL29605173 0.82 KMT2A (0.40) CYP1A2CHRM3KMT2ACYP3A4KDM4E
SCHEMBL11734223 0.81 ATM (0.52) MAPTHIF1AALDH1A1CYP3A4KDM4E
SCHEMBL3381201 0.81 KMT2A (0.45) CYP1A2CHRM3KCNN4MAPTKMT2A
SCHEMBL288100 0.81 MAPT (0.45) CYP1A2CHRM3KCNN4MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109106606-A Topical composition comprising bimatoprost and the method for stimulating hair growth using it 阿勒根公司 2019-01-01 CN claimed
CN-105263469-B Topical compositions comprising bimatoprost and methods of stimulating hair growth therewith 阿勒根公司 2018-11-02 CN claimed
CN-105263469-A Topical compositions comprising bimatoprost and methods of stimulating hair growth therewith ALLERGAN INC 2016-01-20 CN claimed
US-8163698-B2 Dolastatin 15 derivatives ABBOTT GMBH & CO. KG (DE) 2012-04-24 US claimed
US-20100099843-A1 DOLASTATIN 15 DERIVATIVES ABBOTT GMBH & CO. KG (DE) 2010-04-22 US claimed
US-20250019377-A1 1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2025-01-16 US disclosed
CN-109106606-A Topical composition comprising bimatoprost and the method for stimulating hair growth using it 阿勒根公司 2019-01-01 CN disclosed
CN-105263469-B Topical compositions comprising bimatoprost and methods of stimulating hair growth therewith 阿勒根公司 2018-11-02 CN disclosed
CN-108601815-A Peptides and their use in hair treatment 雅芳产品公司 2018-09-28 CN disclosed
US-20170355689-A1 HEPATITIS C VIRUS INHIBITOR BRISTOL MYERS SQUIBB CO (US) 2017-12-14 US disclosed
US-20170355689-A1 HEPATITIS C VIRUS INHIBITOR BRISTOL MYERS SQUIBB CO (US) 2017-12-14 US disclosed
CN-107427479-A The system and method for anti-alopecia-stopping 芙丽雅国际公司 2017-12-01 CN disclosed
US-20090202483-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-08-13 US disclosed
US-20060270606-A1 Dolastatin 15 derivatives ABBOTT GMBH & CO., KG (DE) 2006-11-30 US disclosed
US-7084110-B2 Anticarcinogenic agents for treating cancer; pentapeptides, hexapeptides, heptapeptides, oligopeptides ABBOTT GMBH & CO., KG (DE) 2006-08-01 US disclosed
EP-0991658-B1 DOLASTATIN 15 DERIVATIVES ABBOTT GMBH & CO KG (DE) 2005-12-28 EP disclosed
US-6458765-B1 POLYPEPTIDES AS ANTICANCER AGENTS AND AGAINST CELL PROLIFERATION BASF AKTIENGESELLSCHAFT (DE) 2002-10-01 US disclosed
CN-1328601-A Methods and systems for predicting protein function SCRIPPS RESEARCH INST (US) 2001-12-26 CN disclosed
US-6143721-A FOR TREATING CANCER IN MAMMALS BASF AKTIENGESELLSCHAFT (DE) 2000-11-07 US disclosed
EP-0386839-A2 Tetrahydroquinoline derivatives useful for neurodegenerative disorders MERCK SHARP & DOHME LTD. (GB) 1990-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355689-A1 HEPATITIS C VIRUS INHIBITOR HAVCR2, LIPC, PYGL CYP1A2 2057/4885CHRM3 4012/4885KCNN4 4880/4885
US-20100099843-A1 DOLASTATIN 15 DERIVATIVES DDOST, DBI, DAO CYP1A2 3272/4885CHRM3 4637/4885KCNN4 1836/4885
US-20250019377-A1 1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF CYP11B2, CYP21A2, CYP11B1 CYP1A2 97/4885CHRM3 1574/4885KCNN4 1731/4885
US-20090202483-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS CYP1A2 2139/4885CHRM3 3883/4885KCNN4 4880/4885
US-20060270606-A1 Dolastatin 15 derivatives DDOST, DBI, DAO CYP1A2 3272/4885CHRM3 4637/4885KCNN4 1836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.